SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ARABGOL F.; PANAGHI L.; HAKIM SHOUSHTARI M.; HEBRANI P.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Tehran University Medical Journal Year:2007 | Volume:65 | Issue:9 Page(s): 41-46

Download Full-Text

Persian Verion

View:

1,080

Download:

Cites:

Information Journal Paper

Title

SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Author(s)

ARABGOL F. | PANAGHI L. | HAKIM SHOUSHTARI M. | HEBRANI P. | Issue Writer Certificate

Keywords

REBOXETINEQ3

ATTENTION DEFICIT HYPERACTIVITY DISORDERQ3

Abstract

Background: ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) is a common psychiatric disorder among children and adolescents. This disorder causes difficulties in academic, behavioral, emotional, social and family performance. Stimulants show robust efficacy and a good safety profile in children with this disorder, but a significant percent of ADHD children do not respond adequately or cannot tolerate the associated adverse effects with stimulants. Such difficulties highlight the need for alternative safe and effective medications in the treatment of this disorder. This open-label study assessed the effectiveness of REBOXETINE, a selective norepinephrine reuptake inhibitor, in children and adolescents with ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD).Methods: Fifteen child and adolescent outpatients, aged 7 to 16 (Mean± SD=9.72±2.71) years, diagnosed with ADHD were enrolled in a six open-label study with REBOXETINE 4-6 mg/d. The principal measure of the outcome was the teacher and parent Attention Deficit Hyperactive Disorder Rating Scale (ADHD Rating Scale). Patients were assessed by a child psychiatrist at baseline, 2, 4 and 6 weeks of the medication started. Side effects questionnaire was used to detect side effects of REBOXETINE. Repeated measures Analysis of variance (ANOVA) was done for comparison of Teacher and Parent ADHD Rating Scale scores during the intervention.Results: Twelve of 15 (80%) participants completed the treatment protocol. A significant decrease in ADHD symptoms on teacher (p=0.04) and parent (p=0.003) ADHD rating scale was noted. Adverse effects were mild to moderate in severity. The most common adverse effects were drowsiness/sedation and appetite decrease.Conclusion: The results of the current study suggest the effectiveness of REBOXETINE in the treatment of ADHD in children and adolescents. Double-blind, placebo-controlled studies and larger sample size with long duration of intervention are indicated to rigorously test the efficacy of REBOXETINE in ADHD. It is important that future studies complete our knowledge about safety and side effects of REBOXETINE.

Cites

A COMPREHENSIVE META-ANALYSIS OF THE COMMON INTERVENTIONS IN ADHD

References

No record.

Cite

APA: Copy

ARABGOL, F., PANAGHI, L., HAKIM SHOUSHTARI, M., & HEBRANI, P.. (2007). SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 65(9), 41-46. SID. https://sid.ir/paper/38294/en

Vancouver: Copy

ARABGOL F., PANAGHI L., HAKIM SHOUSHTARI M., HEBRANI P.. SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)[Internet]. 2007;65(9):41-46. Available from: https://sid.ir/paper/38294/en

IEEE: Copy

F. ARABGOL, L. PANAGHI, M. HAKIM SHOUSHTARI, and P. HEBRANI, “SIX WEEK OPEN-LABEL REBOXETINE TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER,” TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), vol. 65, no. 9, pp. 41–46, 2007, [Online]. Available: https://sid.ir/paper/38294/en

Related Journal Papers